BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China..

北京--（商业新闻短讯）--专注于治疗癌症和自身免疫性疾病的领先生物制药公司InnoCare Pharma（香港交易所：09969；苏格兰证券交易所：688428）今天宣布批准研究新药（IND）在中国进行B细胞淋巴瘤-2（BCL2）抑制剂ICP-248联合阿扎胞苷治疗急性髓细胞白血病（AML）的临床试验。。

Acute myeloid leukemia (AML) is a malignant hematological disease originating from hematopoietic stem/progenitor cells, accounting for about 80% of acute leukemia in adults. The risk of developing AML increases with age and is more common in middle-aged and elderly people. AML is also not uncommon in individuals under 18 years old, representing about 15-20% of pediatric leukemia and 80% of leukemia in neonates and infants1..

急性髓细胞白血病（AML）是一种起源于造血干/祖细胞的恶性血液病，约占成人急性白血病的80%。发生AML的风险随着年龄的增长而增加，在中老年人中更为常见。AML在18岁以下的人群中也很常见，约占儿童白血病的15-20%，新生儿和婴儿白血病的80%1。。

BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies. ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor. It has anti-tumor effect by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death..

ICP-248是一种新型的口服生物可利用的BCL2选择性抑制剂。它通过选择性抑制BCL2和恢复程序性细胞死亡机制而具有抗肿瘤作用。。

Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, 'With strong pipeline in hemato-oncology, InnoCare is dedicated to developing therapeutics with diverse mechanisms of action (MoA) to achieve comprehensive coverage of blood tumor indications. ICP-248 is an important global asset of our company in the field of hematology.

InnoCare的联合创始人、主席兼首席执行官Jasmine Cui博士说，“凭借在血液肿瘤学方面的强大渠道，InnoCare致力于开发具有多种作用机制（MoA）的治疗方法，以实现血液肿瘤适应症的全面覆盖。ICP-248是我们公司在血液学领域的重要全球资产。

We will accelerate clinical development and look forward to bringing greater benefits to patients with hematological malignancies early.'.

我们将加快临床开发，并期待尽早为血液系统恶性肿瘤患者带来更大的益处。”

About InnoCare

关于InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States..

InnoCare是一家商业化阶段的生物制药公司，致力于发现、开发和商业化一流和/或一流的药物，用于治疗中国和全球未满足医疗需求的癌症和自身免疫性疾病。InnoCare在北京、南京、上海、广州、香港和美国设有分公司。。